Technology Innovation Institute’s Cryptography Research Centre in Abu Dhabi Collaborates with Yale University
6.1.2021 13:15:00 EET | Business Wire | Press release
Abu Dhabi and the UAE are working to pioneer breakthroughs in post-quantum cryptography and neuromorphic computing through an international partnership between Technology Innovation Institute’s (TII) Cryptography Research Centre (CRC) and Yale University, an Ivy League research university in Connecticut, United States.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005376/en/
Dr. Najwa Aaraj, Chief Researcher at Cryptography Research Centre (Photo: AETOSWire)
The two institutions will first join forces on ‘Post-Quantum Lightweight Crypto Hardware Accelerators and Trusted Execution Environment Designs’, a project at the intersection of emerging technologies that focuses on developing quantum-resistant crypto schemes within the context of emerging quantum algorithms that can be run on a sufficiently large quantum computer. By leveraging post-quantum cryptographic (PQC) algorithms, the project aims to guarantee the necessary measures of security even as today’s public cryptographic standards, such as RSA and Elliptic Curve Cryptography (ECC), become ineffective when a powerful quantum computer is built and can run Shor’s quantum algorithm. The project is also exploring post-quantum lightweight cryptography with a focus on highly constrained devices.
The neuromorphic computing project, ‘Energy-based Probing for Robust and Explainable Spiking Neural Networks’, takes inspiration from the brain to create energy-efficient hardware for information processing and is capable of highly sophisticated tasks. The project examines Spiking Neural Networks (SNNs), which have become popular as an energy-efficient alternative for implementing standard artificial intelligence tasks. Spikes or binary events drive communication and computation in SNNs that are close to biological neuronal processing and offer the benefit of event-driven hardware operations.
The central focus of the collaboration is to explore the design space of the energy-accuracy-robustness-explainability trade-off and to design the hardware/software necessary to create truly functional intelligent systems. To ensure there is no overlap, both entities have been tasked with managing specific areas of the research in both projects.
Speaking on the partnership, Dr Najwa Aaraj, Chief Researcher at Cryptography Research Centre, said: “We are excited to work with peers from Yale University in carrying out groundbreaking research in these two vital fields. At the Cryptography Research Centre, we are creating a knowledge-driven ecosystem powered by like-minded scientists and researchers – all focused on designing breakthrough solutions in different areas of cryptography.”
Jakub Szefer, Associate Professor of Electrical Engineering and Computer Science, and Priya Panda, Assistant Professor of Electrical Engineering, from Yale University, said: “By working collaboratively with Cryptography Research Centre, we have an opportunity to apply shared expertise across post-quantum cryptography and neuromorphic computing research. We are optimistic that this partnership will yield effective research outcomes for greater impact.”
Technology Innovation Institute, the ‘applied research’ pillar of Advanced Technology Research Council (ATRC), is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE. The Institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of the knowledge- based economy.
For more information about Cryptography Research Centre (CRC) please visit
tii.ae/cryptographytii.ae/cryptography
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005376/en/
Contact information
Technology Innovation Institute
Aisha Shaikh, +971555423718
aisha.shaikh@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
